中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (10): 2196-2197.doi: 10.4103/1673-5374.369109

• 观点:退行性病与再生 • 上一篇    下一篇

阿尔茨海默病海马和内嗅皮层谷氨酸能受体表达的变化

  

  • 出版日期:2023-10-15 发布日期:2023-03-28

Metabotropic glutamate receptor 1 alpha: a unique receptor variant with variable implications for Alzheimer’s disease pathogenesis

Jason HY Yeung, Andrea Kwakowsky*   

  1. Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand (Yeung JHY, Kwakowsky A)
    Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, Ollscoil na Gaillimhe - University of Galway, Galway, Ireland (Kwakowsky A) 
  • Online:2023-10-15 Published:2023-03-28
  • Contact: Andrea Kwakowsky, PhD, andrea.kwakowsky@universityofgalway.ie.

摘要: https://orcid.org/0000-0002-3801-4956 (Andrea Kwakowsky)

Abstract: Alzheimer’s disease (AD) is the leading neurodegenerative disorder globally. Despite this, there is minimal effective therapeutics proven to reduce or prevent the progression of this disease. Glutamate is the main excitatory neurotransmitter within the central nervous system and plays a crucial role in neuronal and synaptic functions. As such, the glutamatergic system is finely regulated within normal physiology, with multiple mechanisms to prevent excessive or insufficient glutamatergic receptor activation. This perspective article aims to highlight pertinent findings regarding metabotropic glutamate receptor (mGluR) expression and function in the AD brain, with a particular focus on the mGluR1α variant and its functional significance, concluding with a discussion regarding its potential as a therapeutic target in future AD studies.